⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of PhaseV and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
PhaseV
↗Boston, USA
PhaseV is a Boston-based technology company that leverages advanced causal machine learning and Generative AI to optimize clinical trial design and execution. The company provides a platform that enables biopharma sponsors and CROs to design efficient trials, reduce costs, and increase the probability of success by uncovering hidden patterns in clinical data.
PhaseV's core solutions—including the ClinOps, Trial, Portfolio, and Response Optimizers—support adaptive, Bayesian, and fixed trial designs. The company has partnered with numerous leading pharma/biotech sponsors and CROs across multiple therapeutic areas, including oncology, neurology, immunology, and rare diseases.
CLASSIFICATION
Company Type:Digital Health
Therapeutic Areas:
Industry:Digital Health
Sub-Industry:AI/ML Clinical Trial Optimization
SIZE & FINANCIALS
Employees:1-50
Founded:2023
Ownership:private
Status:operating
FUNDING
Stage:Series A
Total Raised:$65M
Investors:Insight Partners
PIPELINE
Stage:Commercial
Lead Drug Stage:N/A (Technology/Service Provider)
Modalities:AI/ML Platform
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Alimentiv (GI clinical trials), Crohn's & Colitis Foundation, 9xchange (Biopharma marketplace), NeuroSense Therapeutics
COMPETITION
Position:Emerging
Competitors:BenevolentAI, Unlearn.AI, Medidata Solutions, Saama Technologies
LINKS
Website:phasevtrials.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with PhaseV. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.